Clinical Trial Update: TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial of a TCR-T cell therapy targeting KRAS G12V and KRAS G12D mutations in advanced solid tumors; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• TCR-T Cell Therapy targeting KRAS G12V/G12D (KRAS G12V/G12D-targeted T cell receptor therapy)

Snippet

Sponsor: Sun Yat-sen University | Conditions: KRAS G12V, KRAS G12D | EARLY_Phase 1 | Status: NOT_YET_RECRUITING